104 related articles for article (PubMed ID: 20639123)
1. Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy.
Kiran KL; Lakshminarayanan S
Biosystems; 2010 Aug; 101(2):117-26. PubMed ID: 20639123
[TBL] [Abstract][Full Text] [Related]
2. Optimal control in a model of dendritic cell transfection cancer immunotherapy.
Castiglione F; Piccoli B
Bull Math Biol; 2006 Feb; 68(2):255-74. PubMed ID: 16794930
[TBL] [Abstract][Full Text] [Related]
3. Determination of the optimal therapeutic protocols in cancer immunotherapy.
Cappuccio A; Castiglione F; Piccoli B
Math Biosci; 2007 Sep; 209(1):1-13. PubMed ID: 17416392
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy, mathematical modeling and optimal control.
Castiglione F; Piccoli B
J Theor Biol; 2007 Aug; 247(4):723-32. PubMed ID: 17543345
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based cancer therapy.
Conrad C; Nestle FO
Curr Opin Mol Ther; 2003 Aug; 5(4):405-12. PubMed ID: 14513684
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies to improve tumor immunotherapy.
Begley J; Ribas A
Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity.
Lotze MT; Shurin M; Esche C; Tahara H; Storkus W; Kirkwood JM; Whiteside TL; Elder EM; Okada H; Robbins P
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S61-6. PubMed ID: 10685662
[TBL] [Abstract][Full Text] [Related]
8. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
9. Cell fusion: from hybridoma to dendritic cell-based vaccine.
Gong J; Koido S; Calderwood SK
Expert Rev Vaccines; 2008 Sep; 7(7):1055-68. PubMed ID: 18767954
[TBL] [Abstract][Full Text] [Related]
10. [Dendritic cells and their applications in cancer immunotherapy--achievements and future prospects].
Rossowska J; Pajtasz-Piasecka E
Postepy Hig Med Dosw; 2003; 57(5):501-18. PubMed ID: 14737967
[TBL] [Abstract][Full Text] [Related]
11. Current issues in dendritic cell cancer immunotherapy.
López JA; Hart DN
Curr Opin Mol Ther; 2002 Feb; 4(1):54-63. PubMed ID: 11885565
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell based immunotherapy--a promising therapeutic approach for endocrine malignancies.
Sbiera S; Wortmann S; Fassnacht M
Horm Metab Res; 2008 Feb; 40(2):89-98. PubMed ID: 18283626
[TBL] [Abstract][Full Text] [Related]
13. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of the dendritic cell in novel cancer therapies.
Hermans IF; Moroni-Rawson P; Ronchese F; Ritchie DS
N Z Med J; 1998 Apr; 111(1063):111-3. PubMed ID: 9594966
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells for specific cancer immunotherapy.
Meidenbauer N; Andreesen R; Mackensen A
Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
[TBL] [Abstract][Full Text] [Related]
16. Cellular immunotherapy of cancer.
Okur FV; Brenner MK
Methods Mol Biol; 2010; 651():319-45. PubMed ID: 20686975
[TBL] [Abstract][Full Text] [Related]
17. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects.
Fernandez N; Duffour MT; Perricaudet M; Lotze MT; Tursz T; Zitvogel L
Cytokines Cell Mol Ther; 1998 Mar; 4(1):53-65. PubMed ID: 9557217
[TBL] [Abstract][Full Text] [Related]
18. An analysis of variability in the manufacturing of dexosomes: implications for development of an autologous therapy.
Patel S; Mehta-Damani A; Shu H; Le Pecq JB
Biotechnol Bioeng; 2005 Oct; 92(2):238-49. PubMed ID: 16037986
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells and antigen trapping technology--a revolution in vaccine/immunotherapy strategy.
Pal C; Ganguly D; Paul K; Pal S
Indian J Exp Biol; 2007 Jun; 45(6):491-504. PubMed ID: 17585683
[TBL] [Abstract][Full Text] [Related]
20. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
